Clinical Scorecard: Factors Influencing Final Height in X-Linked Hypophosphatemia: The Role of Diagnostic Timing and Initial Growth in a Brazilian Patient Population
At a Glance
Category
Detail
Condition
X-linked hypophosphatemia (XLH)
Key Mechanisms
Impaired phosphate metabolism due to loss-of-function variants in the PHEX gene, leading to increased FGF23 levels and reduced renal tubular phosphate reabsorption.
Target Population
Patients with molecularly confirmed XLH in Brazil.
Care Setting
Tertiary referral center
Key Highlights
Mean height-for-age Z-score at diagnosis was -1.90, indicating significant growth impairment.
Age at diagnosis inversely correlated with final height Z-score.
Final height Z-score among treated patients was -2.96.
Height-for-age Z-score at diagnosis and target height Z-score were independent predictors of final height.
Delayed diagnosis is associated with greater growth deficits.
Guideline-Based Recommendations
Diagnosis
Diagnosis requires clinical and biochemical evidence of XLH, confirmed by molecular testing.
Management
Conventional therapy includes oral phosphate and active vitamin D analogues.
Monitoring & Follow-up
Regular monitoring of height and biochemical parameters is essential.
Risks
Delayed diagnosis can lead to increased orthopedic burden and suboptimal adult height.
Patient & Prescribing Data
Patients with confirmed XLH treated at a tertiary center in Brazil.
Conventional therapy may improve rickets but rarely normalizes serum phosphate levels.
Clinical Best Practices
Early diagnosis is critical to optimize growth trajectories and limit skeletal deformities.
Height measurements should be obtained using standardized methods.
